Momenta Pharmaceuticals (NASDAQ:MNTA) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Momenta Pharmaceuticals and Entera Bio’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Momenta Pharmaceuticals||$75.59 million||18.59||-$176.06 million||($2.03)||-7.02|
Entera Bio has lower revenue, but higher earnings than Momenta Pharmaceuticals.
Insider & Institutional Ownership
96.7% of Momenta Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.9% of Entera Bio shares are owned by institutional investors. 3.7% of Momenta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Momenta Pharmaceuticals and Entera Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Momenta Pharmaceuticals and Entera Bio, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Momenta Pharmaceuticals currently has a consensus target price of $23.54, indicating a potential upside of 65.18%. Entera Bio has a consensus target price of $12.00, indicating a potential upside of 192.68%. Given Entera Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Entera Bio is more favorable than Momenta Pharmaceuticals.
Entera Bio beats Momenta Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn’s disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Entera Bio Company Profile
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.
Receive News & Ratings for Momenta Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.